How can levomepromazine hydrochloride affect blood concentrations of medicines metabolised by CYP2D6?

Levomepromazine hydrochloride and its non-hydroxylated metabolites are reported to be potent CYP2D6 inhibitors, so co-administration may increase plasma concentrations of medicines primarily metabolised by CYP2D6, requiring monitoring for dose-dependent adverse reactions.